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We cannot rebuild him. We do not
have the technology.
Lee Majors will be long dead by the
time we have a real six million dollar
man, but the ¢ve and a half billion
dollar mouse is already with us. It
belongs to Abgenix, Inc. of Fremont,
Calif. At a cost of at least $50 million
dollars, the validation of the
XenoMouse idea ‘‘was a pretty
expensive experiment,’’ says Raju
Kucherlapati of Albert Einstein
College of Medicine in New York.
But the payoff has been enormous.
With Abgenix just passing its fourth
birthday, and all its technology still
tied in some way to the XenoMouse,
Abgenix now commands a valuation
of almost US$5.5 billion. All this for an
idea that was hatched in a company
called Cell Genesys, Inc. (Foster City,
Calif.) that is itself valued just below a
measly US$1 billion. Not a bad jump
in value for a mouse that makes
antibodies.
An idea is born
In a 1985 Nature paper Kucherlapati
showed that mammalian genes could
be modi¢ed by gene targeting. (This
was extended to embryonic stem (ES)
cells in 1987 by Mario Capecchi of the
University of Utah.) ‘‘We began to
think about how this technology could
be commercialized,’’ says
Kucherlapati. ‘‘That led to the
establishment of Cell Genesys.’’
The job of re¢ning the three ideas
that Cell Genesys would focus on
(one being XenoMouse) fell to a
group of scientists and two venture
capitalists from the May¢eld Fund.
Grant Heidrich, still at May¢eld, and
Mark Levin, now CEO of Millennium
Pharmaceuticals, Inc. (Cambridge,
Mass.) ‘‘thought antibodies had great
therapeutic opportunities and there
weren’t good ways to produce them,’’
says Kucherlapati. ‘‘The stimulus was
really from a business/¢nancial point
of view.’’
The scienti¢c idea was to replace a
mouse’s immunoglobulin genes with
human immunoglobulin genes. The
mouse would still see human proteins
as foreign, and could therefore
produce antibodies against human
disease targets. But those antibodies
would be human, and would be
recognized as self by humans. Unlike
the ¢rst generations of mouse-derived
monoclonal antibodies, these
antibodies would not be rejected by
the patient. Antibody half-lives would
soar, allergic reactions would be
avoided, and the tarnished promise of
monoclonal antibodies ¢nally
realized.
Say hello to the (almost) six billion
dollar mouse.
In 1991 Cell Genesys formed a
limited partnership with JT America
Inc., the American division of Japan
Tobacco, Inc., to pursue the
XenoMouse idea. JT put up V$20
million to get the research going.
‘‘In retrospect that was a small
investment,’’ says Kucherlapati. But
it was certainly not an investment
with a guarantee of success. ‘‘Ideas
are a dime a dozen,’’ says
Kucherlapati, ‘‘but you have to be
able to show that they work.’’ At Cell
Genesys that task fell to Aya
Jakobovits, who Kucherlapati
describes as ‘‘a fantastic scientist 9 a
real go-getter.’’
Making the mouse
Initially the researchers planned a
wholesale replacement of human for
mouse immunoglobulin regions.
‘‘Then we recognized that would be a
huge task,’’ says Kucherlapati. The
compromise solution was to delete all
six tandem J, or joining, regions from
the single gene for the heavy chain
immunoglobulins, and to delete a
constant region from the major light
chain gene. The apparatus that
recombines different segments of
DNA to create a ¢nal, expressed
immunoglobulin gene cannot skip
over any one class of segments, so
mice with deleted J regions failed to
produce either immunoglobulins or
mature B cells.
The next task was to insert the
human immunoglobulin genes. Easy
enough, except that the DNA
segments encoding the light and
heavy chains weigh in at around 1.5
Mb each. Jakobovits’ solution was to
fuse yeast spheroplasts, carrying huge
chunks of human immunoglobulin
DNA on yeast arti¢cial chromosomes
(YACs), to mouse ES cells. Random
integration of yeast genomic DNA did
not appear to perturb mouse
development, and integration of the
YAC DNA led to mice that expressed
human antibodies. After all that
hypothesizing and money, here, says
Kucherlapati, was ‘‘the real moment
of triumph.’’
The ¢nished product
The ¢nal XenoMouse was created
after recombining, in yeast, four YACs
to form a 1020-kb heavy chain YAC,
and three YACs to form an 800-kb
light chain YAC. Once the DNA was
integrated, mouse enzymes carried
out normal recombination and af¢nity
maturation to produce functional
antibodies. Each mouse is out¢tted
with a single IgG heavy chain constant
region, so antibodies from some mice
simply block an interaction, whereas
those from other mice recruit immune
effectors that may help kill a target
cell.
While the XenoMouse was being
created, other companies had been
busy coming up with their own
solutions. The simplest was to take an
existing mouse antibody and replace
large chunks with the corresponding
human segments, while leaving the
variable regions intact to preserve
binding speci¢city. This procedure
has led to commercial products, but it
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takes time and can result in a loss of
speci¢c binding af¢nity.
The second alternative is phage
display, in which peptides expressed
on phage are panned for binding of
antigen. Vast numbers of phage can
be screened, but binding af¢nities
in this procedure do not generally
reach the levels seen in antigen^
antibody interactions. Further loss
of binding af¢nity is a great risk
when transferring the peptide
sequence to an antibody framework.
Thus, phage display is suited more to
¢nding low af¢nity reagents that can
be used to test expression patterns or
the effects of binding a certain
protein.
Delivering the goods
The beauty of the antibody concept is
the direct translation from target to
clinical candidate. ‘‘The mouse does
all the work of making the molecule
so you have many fewer people
involved in the process,’’ says
Abgenix chief ¢nancial of¢cer Kurt
Leutzinger. Then, he says, the
incredible speci¢city of the antibody
means that ‘‘we only have to show
that the one thing [the antibody]
binds to is safe enough to bind to.
That really cuts down the time it takes
to get into the ¢rst human trial.’’
Seeing that process in action has
made Leutzinger optimistic about the
future. ‘‘With a reasonable amount of
work we think we can get to a steady
state of two or three IND
[investigational new drug] ¢lings per
year without becoming a huge
company,’’ he says. That stream of
clinical candidates shouldn’t
overwhelm the company, says
Leutzinger, because ‘‘we operate
[only] from immunization to phase II
trials. With that focus we can handle a
lot more products.’’
The company has targets in phase I
and II trials, although some of these
targets are also being pursued by other
companies. Recent deals with
genomics companies are an attempt to
remedy this situation by picking up
some proprietary targets for in-house
development. Meanwhile, Abgenix is
generating income by licensing its
technology to 20 collaborators who
are working on more than 30
antigens.
Antibodies as a quick ¢x
Antibodies are good at targeting
accessible molecules, such as soluble
immune regulators and their receptors
on circulating cells. But antibodies are
also expensive drugs that need to be
injected. According to Geoff Davis,
the chief scienti¢c of¢cer at Abgenix,
‘‘some of our big pharma partners are
using antibodies as a quick entre¤e into
the market, to corner market share.
Certainly you will see some
antibodies replaced by small
molecules.’’ But to Nils Lonberg, the
scienti¢c director at GenPharm
International, Inc. of San Jose, Calif.
(now a division of Medarex, Inc. of
Princeton, New Jersey), ‘‘a lot of that
is wishful thinking.’’ Whereas small
molecules typically jam enzyme
active sites, antibodies are more often
used to interfere with protein^protein
interactions. ‘‘A lot of these
antibodies,’’ says Lonberg, ‘‘will be
around for a long time 9 a lot longer
than many organic chemists expect
them to be.’’ Leutzinger agrees. ‘‘We
think that once antibodies are
established in a market it will be hard
to dislodge them with small
molecules,’’ he says, ‘‘because the
toxicity pro¢le of small molecules is so
much worse.’’
Business ballet
The two things that make Abgenix
stand out are a simple founding
technology and an uncanny ability to
extricate itself from unwanted
contractual situations. The company’s
¢rst and ongoing business
achievement is the separation from
its parent, Cell Genesys. The divorce
began in 1996 when Abgenix was
spun out. Cell Genesys now owns
just 12% of Abgenix’s stock after
selling some holdings and dilution by
further fund-raising. But, says Davis,
‘‘they have over $200 million in the
bank because of the last ¢nancing,
and they still have a stake in Abgenix.
At this point I think everyone is
happy.’’
Abgenix was originally spun out
because its research did not ¢t with
the new gene-therapy focus of Cell
Genesys. ‘‘I doubt that the technology
would have blossomed under one roof
with non-complementary
technologies,’’ says Davis. A similar
rationale drove the separation from
JT, which in December 1999
relinquished its 50% interest in
XenoMouse intellectual property in
return for what now seems a meager
sum of $47 million. ‘‘It was a fantastic
set of events for Abgenix,’’ says
Kucherlapati. ‘‘That is the genius of
[CEO] Scott Greer and [chief
business of¢cer] Ray Withy 9 how
they were able to navigate through
those waters.’’
The third challenge came from
Lonberg and Robert Kay of
GenPharm. They had independently
conceived of and created their own
version of the XenoMouse. Their
injected plasmid constructs encoded
fewer immunoglobulin variable
regions than the Abgenix YACs,
leading Davis to claim that the
Abgenix technology is ‘‘superior.’’ But
Lonberg claims that ‘‘the quality of
the antibodies does not seem to be
dependent on the size of the DNA
that [goes] into the mice,’’ and notes
that GenPharm now has mice with
entire chromosome fragments.
Although Abgenix initiated
litigation against GenPharm, the two
sides soon reached an agreement
allowing both to operate. Abgenix had
to pay up, but once again got off
cheaply. Lonberg, for one, says he
‘‘didn’t want to have a career in
litigation.’’
So now that Abgenix is free from
constraints and rolling in money,
how does it feel for the man who
started it all? Not wanting to crow
too loudly, Kucherlapati goes for
understatement. ‘‘I think,’’ he says,
‘‘we are happy.’’
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